Skip to main content
Device Global Header

Subscribe
or Renew

Advanced Search

This article is available to subscribers. Subscribe now. Already have an account? Sign in

CorrespondenceFree Preview

Pretomanid in the Treatment of Patients with Tuberculosis in the United States

Investigators report findings from the use of an all-oral regimen of bedaquiline, pretomanid, and linezolid in patients in the United States with multidrug-resistant or extensively drug-resistant tuberculosis.

Continue reading this article

Select an option below:

Create your account to get 2 free subscriber-only articles each month.

Get Free Access Now Subscribe For Full Access

Already have an account?

Sign In

Print subscriber?

Activate your online access.

Neela D. Goswami, M.D., M.P.H.
Centers for Disease Control and Prevention, Atlanta, GA

David Ashkin, M.D.
Connie A. Haley, M.D.
University of Florida, Gainesville, FL
for the BAM Project Team

Funding and Disclosures

Disclosure forms provided by the authors are available with the full text of this letter at NEJM.org.

A list of the BAM Project Team investigators is available in the Supplementary Appendix, available at NEJM.org.

Print Subscriber? Activate your online access.